undamentalytics Newsletter
Sign in

Maze Therapeutics, Inc. (MAZE) stock

Add to watchlist

Add holding +

NASDAQ: MAZE Nasdaq Biotechnology Next results ~November 5, 2026

Maze Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 96 sales by directors and officers, last 12 monthsInsider trades
  • Funds102 adding, 76 cuttingOf 51 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 9% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Maze Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 67% and a beta of 0.8 against the S&P 500.
  • Insiders selling. 6 insiders sold $24M of stock over the past 365 days and none bought (90% under pre-set trading plans).
  • Heavily shorted. 15.3% of the shares available to trade are sold short (8.3 days of average volume to cover).

Latest results

Earnings per share
-$0.76 against an average estimate of -$0.70: missed by 9.2%
Share reaction
+0.9% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.75

Maze Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.5%
  • 1 week-2.3%
  • 1 month+14.9%
  • This year-26.7%
  • 1 year-7.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Leadership
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Maze Therapeutics, Inc. valuation models and calculator

No model value for Maze Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.75 (range −$0.87 to −$0.56) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.73 +11% $20m 0%
Next −$3.19 −17% $7m −63%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.0% on 90 days ago. In the last 30 days, 1 analyst raised Maze Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Maze Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.67 Current fiscal year, 60 days ago: −$2.73 Current fiscal year, 30 days ago: −$2.76 Current fiscal year, 7 days ago: −$2.73 Current fiscal year, Now: −$2.73 −$2.73 Next fiscal year, 90 days ago: −$3.19 Next fiscal year, 60 days ago: −$3.18 Next fiscal year, 30 days ago: −$3.18 Next fiscal year, 7 days ago: −$3.22 Next fiscal year, Now: −$3.19 −$3.19

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.67−$3.19
60 days ago −$2.73−$3.18
30 days ago −$2.76−$3.18
7 days ago −$2.73−$3.22
Now −$2.73−$3.19

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.70 −$0.76 −9.2%
Dec 2025 −$0.69 −$0.65 +5.7%
Sept 2025 −$0.69 −$0.66 +4.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

14 analysts, Oct 2026
Buy14100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611314
  2. Sep 202611213
  3. Aug 202611112
  4. Jul 202611112

Counts of recommendations published by analysts covering Maze Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.3%
of tradable shares
Days to cover
8.28
at average volume
Short interest, 1 month
+33%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.6%
of shares
Employees
141
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2026 to date
Return
MAZE−27%
Industry peers (median)−26%
S&P 500+11%
Months that ended higher
MAZE46%
S&P 50046%
Largest fall from a high during the year
MAZE−57%
S&P 500−9%

Worst fall since January 31, 2025: 57% from March 12, 2026 to September 21, 2026. Getting back needed a 132% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$22.39 – $51.84
From 52-week high
−41.4%
vs 50-day average
+10.4%
vs 200-day average
−4.5%
Volatility (1 year)
67%
Beta vs S&P 500
0.77

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 4 down
typical move ±9.7%
After a week
3 up, 4 down
typical move ±12.2%
After a month
3 up, 4 down
typical move ±34.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +0.9% −0.1% +6.8% −9.0%
May 12, 2026 +5.6% +0.4% −4.2% −5.6%
March 25, 2026 −35.3% −1.2% −40.7% −47.3%
November 6, 2025 −5.5% −1.0% +5.2% +37.0%
August 12, 2025 +1.0% +1.4% −0.1% +84.1%
May 14, 2025 −6.2% +0.6% +6.7% +35.9%
March 31, 2025 −13.3% +1.0% −21.9% −19.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$1.7B
Institutions reporting
161
Shares held vs prior quarter
▲ 13.3%
Positions opened / closed
37 / 38

Top buyers and sellers, Q2 2026: 102 institutions bought and 76 sold ; the biggest buyer was T. Rowe Price Investment Management, Inc (+2.6M shares) and the biggest seller Paradigm Biocapital Advisors LP (−2.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Frazier Life Sciences Management, L.P. $150M 5.0M 8.6% ▲ 10.2%
Trv Gp Iv, LLC $134M 4.5M 7.6% 0.0%
Arch Venture Management, LLC $123M 4.1M 7.0% 0.0%
Deep Track Capital, LP $111M 3.7M 6.4% ▲ 7.3%
Blackrock, Inc. $105M 3.5M 6.0% ▲ 36.3%
Jupiter Topco LLC $102M 3.4M 5.8% —
T. Rowe Price Investment Management, Inc. $77.7M 2.6M 4.5% New
Logos Global Management LP $57.7M 1.9M 3.3% ▲ 56.7%
Vanguard Capital Management LLC $53.1M 1.8M 3.0% ▲ 23.9%
A16Z Capital Management, L.L.C. $50.8M 1.7M 2.9% 0.0%
Venrock Adviser, LLC $47.8M 1.6M 2.7% 0.0%
Alphabet Inc. $41.4M 1.4M 2.4% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Maze Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $23.9M 96 trades by 6 insiders · 90% under pre-set plans
Net ▼ $23.9M net selling
Insider Date Trade Shares Price Value
Dandekar Atul CSBO October 29, 2026 Sell pre-set plan 7,500 $32.07 $240,532
Bernstein Harold President, R&D & CMO October 1, 2026 Sell pre-set plan 16,141 $26.93 $434,743
Coloma Jason V Chief Executive Officer October 1, 2026 Sell pre-set plan 31,908 $27.02 $862,186
Coloma Jason V Chief Executive Officer October 1, 2026 Sell pre-set plan 2,593 $27.02 $70,073
Dandekar Atul CSBO September 29, 2026 Sell pre-set plan 7,500 $27.06 $202,921
Bernstein Harold President, R&D & CMO September 4, 2026 Sell pre-set plan 9,705 $26.22 $254,465
Bernstein Harold President, R&D & CMO September 3, 2026 Sell 5,130 $26.01 $133,431
Bernstein Harold President, R&D & CMO September 3, 2026 Sell 59 $25.78 $1,521
Coloma Jason V Chief Executive Officer September 3, 2026 Sell 11,282 $26.01 $293,445
Coloma Jason V Chief Executive Officer September 3, 2026 Sell 129 $25.77 $3,324
Dandekar Atul CSBO September 3, 2026 Sell 36 $25.81 $929
Dandekar Atul CSBO September 3, 2026 Sell 3,207 $26.01 $83,414

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 25, 2026
  • November 6, 2025
  • August 12, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Maze Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Maze Therapeutics, Inc. in brief

What does Maze Therapeutics, Inc. do?
Maze Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Maze Therapeutics, Inc.'s stock ticker?
Maze Therapeutics, Inc. trades under the ticker MAZE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Maze Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Frazier Life Sciences Management, L.P., Trv Gp Iv, LLC and Arch Venture Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Maze Therapeutics, Inc. stock?
Over the last 12 months, Maze Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 96 sales on Form 4. The insider trading page charts every trade.
When is Maze Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Maze Therapeutics, Inc. announces its own schedule.